Carbon ion radiotherapy for thymus tumors after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the effectiveness and side effects of carbon ion radiotherapy in patients with advanced thymic epithelial tumors that have undergone R2 resection. Participants will receive a total of 72GyE delivered in 18 fractions, combined with a platinum-based chemotherapy regimen for at least four cycles. The primary focus is on progression-free survival and toxicity, while secondary outcomes include local relapse-free survival, overall survival, and cause-specific survival. The study aims to provide insights into the potential benefits of this innovative treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with stage II-IV (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiotherapy who had undergone radical surgery (R2 resection, visible residual tumor) and had a definite pathological diagnosis.
* Sign informed consent.
* Between the ages of 18 and 70.
* ECOG general status score of 0-2.
* The expected survival is at least 6 months.
* Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1\>25%, DLCO\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \<1.5 times the upper limit of normal value, and AST, ALT\<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein \<2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.

Exclusion Criteria:

* Complicated with other malignant tumors that have not been controlled.
* Have large quantity of pleural or pericardial effusion.
* Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.
* Chest radiation therapy or radioactive particle implantation history.
* Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.
* Pregnancy (confirmed by serum or urine β-HCG test) or lactation period.
* HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.
* A history of mental illness may hinder the completion of treatment.
* With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.
* Other circumstances that the physician considers inappropriate to participate in clinical study.

Where it's running

• Shanghai Proton and Heavy Ion Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Jingfang Mao, PHD — Shanghai Proton and Heavy Ion Center
• Study coordinator: Jing Li
• Email: jing.li@sphic.org.cn
• Phone: 86-21-38296678

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using carbon ion radiotherapy to treat high-grade glioma

  This study is testing a new type of radiation therapy using carbon ions combined with regular radiation to see if it can help people with high-grade glioma live longer and have fewer side effects.

  Recruiting Gansu Wuwei Tumor Hospital · Wuwei, Gansu · NCT06831773

• Carbon ion lattice radiotherapy for large thoracic tumors

  This study tests a carbon ion lattice radiotherapy approach, after induction chemoimmunotherapy, in adults with unresectable locally advanced NSCLC or other thoracic solid tumors.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07744074

• Postoperative Hypofractionated Radiotherapy for Stage II/III Thymic Epithelial Tumors

  This study tests whether giving a shorter course of higher-dose radiotherapy after complete tumor removal is safe for adults with Stage II/III thymic epithelial tumors.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07691619

• Self‑manual lymph drainage for head and neck lymphedema

  This trial will test whether different intensities of self‑applied manual lymph drainage help people with head and neck lymphedema after radiotherapy for oropharyngeal cancer.

  Recruiting Lund University · Lund, Skåne County · NCT07215169

• Health-Oriented Protocol for Epidermal Radiodermatitis

  This study looks at how skin reactions from radiation therapy affect adults with head/neck or pelvic cancers and whether certain factors influence RID outcomes.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT07129525

• Skipping the clinical target volume (CTV) around the primary tumor in limited-stage small cell lung cancer

  This trial tests whether giving chest radiotherapy that skips the usual extra margin around the main tumor is as effective and causes fewer side effects for people with limited-stage small cell lung cancer who have responded to initial chemotherapy.

  Recruiting at 2 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07008716

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.